A Phase 2/3 interventional study of Furosemide Pill 150% equivalent iv dose and Furosemide Pill 200% equivalent iv dose in Heart Failure, sponsored by Jan Kochanowski University. Withdrawn at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Jan Kochanowski University · Phase 2/3, Interventional, and Treatment
The goal of this clinical study is to compare treatment regimens of loop diuretics in patients with decompensated heart failure. The main aim is to answer if early change from intravenous to oral loop diuretics is safe and effective.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
Browse Heart Failure studies →Jan Kochanowski University is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient hospitalized due to exacerbation of heart failure symptoms, where AHF is the main cause of hospitalization. To be included in the study, all criteria 1 to 6 must be met:
Fluid Retention Features:
The concentration of natiuretic peptides must be assessed within 24 hours of admission to the hospital and be:
✔ NTpro-BNP >450 pg/mL for \<55 years, 900 pg/mL for 55-75 years, and >1800 pg/mL for >75 years
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
prolonged intravenous loop diuretic treatment - furosemide
Drug: Furosemide Injection
Early (48 hrs) change to oral loop diuretic - furosemide - 150% eqivalent iv dose
Drug: Furosemide Pill 150% equivalent iv dose
Early (48 hrs) change to oral loop diuretic - furosemide - 200% eqivalent iv dose
Drug: Furosemide Pill 200% equivalent iv dose
change from intravenous to oral furosemide
change from intravenous to oral furosemide
change from intravenous to oral furosemide
number of patients requiring hospitalization
any hospitalization due to cardiovascular reasons
Time frame: 12 weeks
Time to hospitalization measured in days
Time to any hospitalization due to cardiovascular reasons
Time frame: Up to 12 weeks
Death
Cardiovascular death
Time frame: 12 weeks
New York Heart Association NYHA class
NYHA class assessment
Time frame: 6 and12 weeks
assessment of quality of life
QoL by Minnesota questionnaire
Time frame: 12 weeks
This study is withdrawn, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jan Kochanowski University